

Date: 19/05/2021

FREEDOM OF INFORMATION REQUEST FOI/015676 - Cancer treatments (biologics)

Numbers are as follows:

1. How many patients were treated (for any condition) in the past 6 months with:

Abiraterone 31
Apalutamide 0
Cabazitaxel 0
Darolutamide 0
Docetaxel 69
Enzalutamide 50
Ruxolitinib 11

2. Please provide the total number of patients treated in the last 6 months for Myelofibrosis (ICD10 code D47.4) - 0 (on chemocare)

Myelofibrosis (ICD10 code D47.4) - patients over the age 65 0 (on chemocare)

Prostate cancer - 80

Metastatic prostate cancer - (no distinction on chemocare for metastatic prostate)

3. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years? - As per NHS Digital rules the Trust not publish numbers lower than 5 as this could lead to the identification of the persons involved.

Of these patients, how many were treated in the past 6 months with Hydroxyurea? - 0

Of these patients, how many have received no active treatment in the past 6 months? - 0

4. How many metastatic prostate cancer patients were treated in the past 6 months with:

Abiraterone 31
Apalutamide 0
Cabazitaxel 0
Darolutamide 0
Docetaxel *
Enzalutamide *

** Docetaxel and Enzalutamide - number added together = 54. (See response to question 3)